Laura Brege - Dynavax Technologies Director
| DVAX Stock | USD 11.80 0.46 4.06% |
Director
Ms. Laura A. Brege serves as Independent Director of Dynavax Technologies Corporationrationration. Ms. Brege was a member of our Board since February 2015. Since September 2015, she has served as managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and VC industries. From September 2012 to July 2015, Ms. Brege was President and Chief Executive Officer of Nodality Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms. Brege held several seniorlevel positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, from 2006 until 2012, including positions as Executive Vice President and Chief Operating Officer. While at Onyx she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a VC firm specializing in early stage financing for technology companies. Previously Ms. Brege was Senior Vice President and Chief Financial Officer at COR Therapeutics, where she helped build the company from an early stage RD company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the board of directors of the following public pharmaceutical companies Acadia Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc. and HLS Therapeutics, Inc., a pharmaceutical company since 2015.
| Age | 60 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0106) %, meaning that it created substantial loss on money invested by shareholders. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 19.9 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Eran Nadav | Collegium Pharmaceutical | 45 | |
| Michael Zasloff | Amphastar P | 72 | |
| Richard Koo | Amphastar P | 77 | |
| Nancy Wysenski | Alkermes Plc | 60 | |
| Robert Breyer | Alkermes Plc | 73 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| Judith Robertson | Durect | N/A | |
| David Pernock | Eagle Pharmaceuticals | 63 | |
| Meredith Kaya | Ironwood Pharmaceuticals | N/A | |
| Susan Kelley | Deciphera Pharmaceuticals LLC | 63 | |
| John Cochran | Aquestive Therapeutics | 52 | |
| Jon Saxe | Durect | 81 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Gary Pace | Pacira Pharmaceuticals | 70 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Gail Farfel | Durect | 53 | |
| Dennis Winger | Pacira Pharmaceuticals | 68 | |
| Andrew Dreyfus | Ironwood Pharmaceuticals | 59 | |
| Michael Rawlins | Intracellular Th | 72 | |
| Floyd Bloom | Alkermes Plc | 80 | |
| Mark Schobel | Aquestive Therapeutics | 61 | |
Management Performance
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arnold Oronsky, Independent Chairman of the Board | ||
| Francis Cano, Independent Director | ||
| Daniel Kisner, Independent Director | ||
| Dennis Carson, Independent Director | ||
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
| Eddie Gray, CEO and Director | ||
| Peggy Phillips, Independent Director | ||
| Nicole Arndt, Sr Relations | ||
| Laura Brege, Director | ||
| David Johnson, Chief Accounting Officer, Vice President | ||
| Andrew Hack, Director | ||
| John Slebir, Senior Counsel | ||
| Jeff Coon, CHRO Administration | ||
| Meg Smith, VP Operations | ||
| Todd Lopeman, Senior Operations | ||
| Stanley Plotkin, Independent Director | ||
| Dan Kisner, Independent Director | ||
| Riccardo Manetti, Business President | ||
| Eric Frings, Site VP | ||
| Natale Ricciardi, Director | ||
| David Novack, Sr. VP of Operations and Quality | ||
| Donn Casale, Chief Officer | ||
| Kelly MacDonald, Senior CFO | ||
| Paul Cox, VP Communications | ||
| Dong Yu, Senior Research | ||
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
| Robert Coffman, Chief Scientific Officer and Sr. VP | ||
| Justin Burgess, Principal Controller | ||
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 995.78 M | ||||
| Shares Outstanding | 130.86 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 17.97 M | ||||
| Price To Earning | 6.95 X |
Dynavax Technologies Investors Sentiment
The influence of Dynavax Technologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Dynavax. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Dynavax Technologies' public news can be used to forecast risks associated with an investment in Dynavax. The trend in average sentiment can be used to explain how an investor holding Dynavax can time the market purely based on public headlines and social activities around Dynavax Technologies. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dynavax Technologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dynavax Technologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Dynavax Technologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Dynavax Technologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dynavax Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dynavax Technologies' short interest history, or implied volatility extrapolated from Dynavax Technologies options trading.
Pair Trading with Dynavax Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dynavax Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dynavax Technologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Dynavax Stock
| 0.7 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Dynavax Stock
| 0.58 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.52 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.45 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Dynavax Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dynavax Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dynavax Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dynavax Technologies to buy it.
The correlation of Dynavax Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dynavax Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dynavax Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dynavax Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.05) | Revenue Per Share 1.804 | Quarterly Revenue Growth (0.70) | Return On Assets (0.02) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.